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INTRODUCTION
One of the impacts of the improved health develop-
ment in Indonesia is the increase of life expectancy,
from 64.71 years (1995 - 2000) to 67.68 years (2000
- 2005), and it is estimated that elderly proportion in
2005 will be of 8.4% or 18.4 million people. This
conditions, makes Indonesia be the fourth country in
Abstract
Objective: To evaluate the role of estrogen as a menopausal bio-
chemical marker to c-telopeptide (CTx) and IL-6 as a biochemical
marker of mineral bone density in perimenopausal women.
Method: This is an observational, cross-sectional study in peri-
menopausal women between 45 - 51 years old, who matched the in-
clusion and exclusion criteria such as no contraception was taken
before, no specific disease that could affect the laboratory findings.
Samples were taken from outpatients clinic of Prof Dr. R.D. Kandou
hospital. The patients were gathered for blood samples collection.
Blood samples were tested in laboratory. All data were collected and
being processed statistically using Pearson correlation coefficient
(SPSS version 16).
Result: From 60 perimenopausal women (45 - 51 years old)
sample, mean age was 47.98 ± 2.26 SD. Estrogen (estradiol) level:
< 10 pg/ml, maximum 358 pg/ml, and mean 77.11 ± 86.2 SD. IL-6
level: minimum is 1.645 pg/ml, maximum 7.771 pg/ml, and mean
4.317 ± 2.112 SD. We found significant correlation between age and
estrogen level (correlation level < 0.05) and CTx level (in level <
0.01). From regression curve, age has no significant correlation with
IL-6 concentration. However, we found significant correlation bet-
ween estradiol and CTx and IL-6 with respective correlation coeffi-
cient value of < 0.01. Likewise the correlation between CTx and IL-
6 showed significant statistically with the value of the correlation
coefficient < 0,01.
Conclusion: There is a significant correlation between estrogen,
Il-6 and CTx. These variables play an important role in the occur-
rence of the physiological changes in the perimenopausal women.
This study also showed the occurrence of a bone reabsorption pro-
cess that was marked by the increase of CTx level in accordance
with the increase in the age and the increase in the level of CTx to-
gether with the decline in the level of oestrogen. Therefore, preven-
tion therapy of osteoporosis should begin in earlier age, before the
further bone reabsorption take place.
[Indones J Obstet Gynecol 2010; 34-2: 84-8]
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Abstrak
Tujuan: Mengetahui peran estrogen sebagai penanda biokimia-
wi menopause terhadap c-telopeptide (CTx) dan IL-6 sebagai pe-
nanda biokimiawi penurunan densitas mineral tulang pada perem-
puan perimenopause.
Metode: Penelitian ini adalah suatu studi observasional dengan
pendekatan studi potong lintang (cross sectional) pada perempuan
perimenopause usia 45 - 51 tahun yang memenuhi kriteria inklusi
dan eksklusi. Faktor-faktor yang dapat mempengaruhi estrogen dan
progesteron dikeluarkan dari sampel. Sampel diambil di Poliklinik
RSUP Prof. Dr. R.D. Kandou Manado. Para pasien dikumpulkan
pada hari tertentu untuk kemudian diperiksakan darahnya, peme-
riksaan darah dilakukan di laboratorium swasta. Data yang ada
dikumpul dan diolah secara statistik dengan menggunakan koefi-
sien korelasi dari Pearson, dengan menggunakan program SPSS,
versi 16.
 Hasil: Dari 60 sampel perempuan usia perimenopause (45 - 51
tahun) diperoleh mean usia sebesar 47,98 ± 2,26 SD. Kadar estro-
gen (estradiol) minimum diperoleh < 10 pg/ml sedangkan nilai
maksimum sebesar 358 pg/ml dengan mean sebesar 77,11 ± 86,2
SD. Kadar CTx minimum diperoleh sebesar 0,03 μg/l, nilai mak-
simum sebesar 1,21 μg/l dengan mean sebesar 0,377 ± 0,226 SD.
Kadar IL-6 minimum sebesar 1,645 pg/ml, nilai maksimum didapat-
kan sebesar 7,771 pg/ml dengan mean sebesar 4,317 ± 2,112 SD.
Ditemukan suatu korelasi signifikan antara usia dengan kadar es-
trogen (pada level korelasi < 0,05) dan dengan kadar CTx (pada
level < 0,01), dari kurva regresi, usia tidak memiliki korelasi signi-
fikan terhadap konsentrasi IL-6. Namun korelasi signifikan antara
estradiol dengan CTx dan IL6 dengan nilai koefisien korelasi ma-
sing-masing sebesar < 0,01. Demikian juga korelasi antara CTx
dengan IL-6 menunjukkan signifikan secara statistik dengan nilai
koefisien korelasi < 0,01.
Kesimpulan: Terdapat suatu korelasi signifikan antara Estro-
gen, IL-6 dan CTx di mana variabel ini dianggap saling berperan
dalam terjadinya perubahan fisiologis pada perempuan perime-
nopause. Studi ini juga menunjukkan telah terjadinya suatu proses
reabsorbsi tulang yang ditandai dengan meningkatnya kadar CTx
sesuai dengan pertambahan usia dan meningkatnya kadar CTx se-
iring dengan menurunnya kadar estrogen. Dengan demikian, terapi
pencegahan osteoporosis dapat dimulai pada usia ini, sebelum ter-
jadi proses reabsorbsi tulang lebih jauh.
[Maj Obstet Ginekol Indones 2010; 34-2: 84-8]
Kata kunci: c-telopeptide, densitas mineral tulang, estrogen, in-
terleukin-6, perempuan perimenopause
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the world after China, India, and United States with
elderly population. Thus, Indonesia will face some de-
generation problems such as perimenopausal women
(45 - 51 years old), e.g. osteoporosis.1 Perimenopause
is a moment of which goes in the direction of meno-
pause with normal ovarial cycle until complete end
of menstruation.2 This periode can be identified from
the beginning of irregular menstrual period until the
total menstruation cessation.
One problem take place in perimenopausal women
is the decrease of bone mineral density as the result
of decrease in estrogen level. Analysis held by the
Nutrition Experimental and Development Center in
Department of Health in 14 provinces showed that
osteoporosis problem in Indonesia has achieved a cau-
tion level, which is 19.7%. The incidence of osteo-
porosis in Indonesia is 6 times higher than in Nether-
land. Five provinces with the highest risk of osteo-
porosis were South Sulawesi (27.7%), Middle Java
(24.02%), Yogyakarta (23.5%), North Sumatera
(22.82%), East Java (21.42%) and East Kalimantan
(10.5%). Another study in Jakarta, Bandung, Sema-
rang, Surabaya, and Medan in 2002 also showed that
osteoporosis in Indonesia should have been cautioned.
Of 101.161 respondents, there were 29% (include pe-
rimenopausal and menopausal women) have suffered
from osteoporosis.3
Regarding the needs of early prevention of the de-
crease in bone mineral density, researchers think that
it is necessary to research about estrogen role as bio-
chemical marker in menopause against c-telopeptide
(CTx) and IL-6 as the biomechanical marker of bone
mineral density in perimenopausal women.
Decrease of bone mineral density denotes a chronic
continuous processes that leads to osteoporosis. De-
crease of bone mineral density in perimenopausal
ages result in high fragility fracture rate in this group
of age. Examination with DEXA is a gold standard
to determine the diagnosis of osteoporosis. The clini-
cal fact shows that osteoporosis is often diagnosed
after fracture. Subsequently, there is a necessity of a
dependable biomarker and individual susceptibility to
experience osteoporosis.4
Estrogen level could be used as a biomarker from
the beginning of perimenopausal period. Perimeno-
pause will started when the estrogen level reach 108
pg/ml and in the late perimenopause the estrogen level
reach 48 pg/ml.5-7 Estrogen influence bone resorption
through estrogen receptor in osteoclast and osteo-
blast.8 Hipoestrogenic environment such as in peri-
menopause period will decrease calcium absorbtion
in the bowel.9 Consequently, in the perimenopause
period, series of bone catabolic activity that leads to
osteoporosis will take place. Estrogen influences cal-
cium absorption from the bowel and excretion
through kidney. Its other main benefit is blockage of
bone calcium resorption. Within the premenopausal
period, estrogen maintains bone mass through block-
ing the activity of parathyroid hormone (PTH) and
increasing calcitonin.10
Estrogen deficiency results in the increase of pro-
inflammatory cytokine production in the bone mi-
croenvironment. Those cytokine are: IL-1, IL-6, TN-
Fα, GM-CSF (Granulocyte-Macrophage Colony Sti-
mulating Factor), and Prostaglandine E2. Those cy-
tokine acts through increasing pool of proosteoclast
inside the bone marrow.11 IL-6 was the chosen cy-
tokine in this experiment as in vitro experiment shows
that IL-6 has a positive role in osteoclastogenesis.12,13
Bone degradation marker is a C-telopeptide and N-
telopeptide, whereas bone matrix production marker
is alkali phosphatase.14 In the past, alkali phosphatase
was used to identify osteoblast activity, whereas bone
resorption marker is hidroxyproline. The better under-
standing then shows that both parameters have low
sensitivity and specificity.15 Compared to other mark-
ers, CTx has a better sensitivity and more accurate
result in measurement of serum(13). C-telopeptide16,17,
IL-64,18, are biomarkers that have effect in bone mi-
neral density. Those factors make new hope that os-
teoporosis in the future could be predicted earlier be-
fore significant decrease of bone mineral density and
fracture occur. Fracture in osteoporosis patients need
more time to heal and decrease patient’s quality of
life.19,20
Relationship between serum estrogen concentration
and C-telopeptide (CTx) and relationship between se-
rum estrogen concentration and IL-6 need to be exa-
mined. Estrogen as a biomarker against perimeno-
pause, whereas CTx and IL-6 as biomarkers of bone
catabolism might be influence each other. If there is
a correlation, we look forward for a further study that
could be done to find whether CTx and IL-6 level
could be used as a predictor of decrease in bone mi-
neral density in the future.
METHOD
This is a cross sectional observational study in peri-
menopausal women, age of 45 - 51 years who meet
inclusion criteria. Data were analyzed to see the mo-
tive-consequence relationship (correlation). Study po-
pulation is perimenopausal women present in the out-
ward obstetric-gynecologic clinic Prof. dr. R.D. Kan-
dou Manado General Hospital. Study sample is com-
ponent of study population who meets the inclusion
and exclusion criteria.
1. Inclusion criteria are:
Perimenopausal women 45 - 51 years old, sign
the informed consent to participate in this study,
clinically healthy, except problems of bone ten-
derness without certain disease, free from hormo-
nal contraception for the last 6 months, BMI
within normal range, never had fracture before
experiment, non-smoker (active and passive).
2. Exclusion criteria:
Lysis or damage sample through examination pro-
cess, factors listed in Table 1, consumption of
certain drugs which will affect bone metabolism
21: glucocorticoids, cyclosporine, cytotoxic drug,
anticonvulsant, alcohol, aromatase inhibitor, thy-
roxine, aluminum, GnRH agonist, heparin, lithi-
um.
Several other factors despite estrogen hormone de-
ficiency in perimenopausal period affect the risk of
osteoporosis, subsequently those factors should be va-
nished away to prevent affecting experimental result.
Those factors are listed in Table 121:
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Table 1. Factors affecting bone mineral density other than es-
trogen deficiency in menopausal period.21
Hypogonadal states Hematologic disorders/
malignancy
Turner syndrome Multiple myeloma
Klinefelter syndrome Lymphoma and leukemia
Anorexia nervosa
Hypothalamic
amenorrhea
Malignancy-associated para-
thyroid hormone (PTHrP)
production
Hyperprolactinemia Mastocytosis
Other primary or secondary
hypogonadal states
Hemophilia
Thalassemia Selected inherited disorders
Endocrine disorders Osteogenesis imperfecta
Cushing’s syndrome Marfan syndrome
Hyperparathyroidism Hemochromatosis
Thyrotoxicosis Hypophosphatasia
Type 1 diabetes mellitus Glycogen storage Diseases
Acromegaly Homocystinuria
Adrenal insufficiency Porphyria
Nutritional and gastro-
intestinal disorders
Ehlers-Danlos Syndrome
Malnutrion Menkes’ syndrome
Parenteral nutrition Epidermolysis bullosa
Malabsorption syndromes Other disorders
Gastrectomy Immobilization
Severe liver disease, espe-
cially biliary cirrhosis
Chronic obstructive pul-
monary disease
Pernicious anemia Pregnancy and lactation
Rheumatologic disorders Scoliosis
Rheumatoid arthritis Multiple sclerosis
Ankylosing spondylitis Sarcoidosis
Amyloidosis
Correlation test was done by Pearson test to deter-
mine the correlation between estrogen and CTx and
IL-6.
RESULTS
During study period, 60 perimenopausal women were
obtained. Each sample was evaluated for estradiol,
CTx, and IL-6 level and analyzed statistically.
Sample Characteristics
Of 60 perimenopausal women samples (45 - 51 years
old), the age mean was 47.98 ± 2.26 SD. Minimum
estrogen (estradiol) level was 10 pg/ml, whereas
maximum estrogen level was 368 pg/ml with mean
of 77.11 ± 86.2 SD. Minimum CTx level was 0.03
μg/l, maximum level was 1.21 μg/l, with mean of
0.377 ± 0.226 SD. Minimum IL-6 level was 1.645
pg/ml, maximum level was 7.771 pg/ml, with mean
of 4.317 ± 2.112 SD.
There is a significant correlation between maternal
age and estradiol serum concentration. The estradiol
level tend to decrease as the maternal age advance
(Figure 1). From the statistical analysis, we found
there is no correlation between maternal age and IL-6
serum concentration. This finding is not in accordance
with the theory that state IL-6 serum would increase
as the maternal age advanced.
There is a significant correlation between maternal
age and CTx serum concentration. The CTx level tend
to increase as maternal age advanced (Figure 2).
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Figure 1. Correlation between age and estrogen concentration
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There is a signifficant correlation between the es-
tradiol serum and IL-6 serum concentration. From the
linear curve we could concluded that as the serum
estradiol concentration increase, the IL-6 concentra-
tion decrease. (Figure 3)
As the linear curve between estradiol and IL-6, the
linear curve between estradiol and CTx also show a
same correlation, decrease of CTx concentration as
the estradiol concentration decrease. (Figure 5)
DISCUSSION
Statistic data analysis found a significant correlation
between age and estrogen level (correlation level <
0.05) and with CTx level (level < 0.01). This is in
accordance with the theory that elderly population
will have ovarian function decreased. Thus, bone re-
modelling process will be shifted to negative direc-
tion. Further data analysis shows that age does not
have significant correlation with IL-6 concentration.
The reason is so many factors affecting IL-6 level in
blood, such as immunity and. Correlation of age and
IL-6 in this experiment was contradictive with Xu et
al (2003) study which stated that the more increase
of age, the higher serum IL-6 level and results in it
the more bone mass decrease. Other potential cause
of the difference between this study and Xu et al is
because Xu’s experiment was done in women with
age older than 50 years old, so the more significant
correlation was drawn, compared to this experiment,
with younger age range (45 to 51 years old).
Further statistical analysis shows significant corre-
lation between estradiol with CTx and IL-6 with co-
efficient correlation each of < 0.01. The correlation
between CTx and IL-6 also shows statistically signi-
ficant coefficient correlation of < 0.01. To observe
those correlations more clearly, we try to describe the
correlation through regression curve.
It is shown that relationship between age and es-
trogen (estradiol) level build a linear curve with co-
efficient regression (R2 = .047), also correlation be-
tween age and CTx level has R2 = .105. Correlation
between age and IL-6 also build linear curve with R2
= .012, though their correlation was not significant
statistically. Correlation between estrogen level with
CTx and IL-6 build a linear curve with coefficient
regression each of R2 = .216 and R2 = .152. The last
was correlation between IL-6 and CTx, a linear curve
was built with R2 = .397.
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The limitation of this study is that the bone mineral
density was not examined because of limited facility
in our centre. DMT examination should be done using
DEXA (Dual Energy X-ray Assay) which is a gold
standard for DMT examination. DMT examination
was needed to evaluate to which extent the bone re-
sorption process take place, and to confirm laboratory
examination results.
CONCLUSION
There was a significant correlation between estrogen,
IL-6 and CTx, the variable of which act each other
in occurrence of physiologic changes of perimeno-
pause women. Subsequently, osteoporosis prevention
therapy should be started in this age, before further
bone reabsorption process take place.
Further study to compare estrogen, IL-6, and CTx
level in bone mineral density using DEXA in peri-
menopausal women was needed to further observe the
perimenopause impact in those women.
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